http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20010024044-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| filingDate | 1998-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20010024044-A |
| titleOfInvention | Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c |
| abstract | The present invention relates to the use of IFN-α in combination with amantadine for the manufacture of a medicament for the treatment of chronic hepatitis C. The present invention provides a medicament containing IFN-α and amantadine as a combined formulation for use simultaneously, separately or continuously in the treatment of chronic hepatitis C. The present invention includes administering an amount of IFN-α effective to treat hepatitis C, together with an amount of amantadine effective to treat hepatitis C, in a patient in need thereof for the treatment of chronic hepatitis C. Also provided are methods for treating hepatitis C. |
| priorityDate | 1997-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.